# Hartmut Döhner

Source: https://onco.cc/people/hartmut-dohner/  
OnCo record `hartmut-dohner` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide.

## Summary

Hartmut Döhner (Ulm) chairs the European LeukemiaNet AML working group and is first author of the 2010, 2017 and 2022 ELN recommendations that define AML genetic risk groups and response criteria used in every trial and clinic. He leads the German-Austrian AML Study Group, whose trials characterised NPM1, CEBPA and FLT3 mutations as prognostic markers, and co-led the WHO/ELN genomic classification.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: aml; classification; guidelines
- Role: Medical Director, Department of Internal Medicine III, Ulm University Hospital
- Specialisms: Acute myeloid leukaemia; Genomic classification; Risk stratification; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Dohner%20H%5BAuthor%5D%20acute%20myeloid%20leukemia%20ELN

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [FLT3](https://onco.cc/targets/flt3/)
- institutions: [Ulm University Hospital / Comprehensive Cancer Center Ulm](https://onco.cc/institutions/ulm-university-hospital/)

---
JSON: https://onco.cc/api/v1/entities/hartmut-dohner.json